• SAR405 and the Energy-Stress Axis: Precision Tools for Vps34

  2026-04-30

  Explore how SAR405, a leading Vps34 inhibitor, empowers researchers to dissect autophagy under energy stress with unprecedented specificity. Discover new insights bridging AMPK signaling, lysosomal dynamics, and advanced assay design.

• Toremifene’s Role in Breast Cancer Therapy: 20 Years Reviewe

  2026-04-30

  This review examines two decades of clinical data on toremifene, highlighting its efficacy and safety as a selective estrogen receptor modulator (SERM) for hormone receptor-positive breast cancer. The findings demonstrate the importance of precision medicine and biomarker-driven therapy, contextualizing toremifene’s place relative to aromatase inhibitors and supporting ongoing research into estrogen biosynthesis inhibition.

• Nanozyme Eradication of Intramacrophage Bacteria in CRC Immu

  2026-04-29

  This study details the engineering of self-activatable polymeric nanozymes targeting Fusobacterium nucleatum within tumor-associated macrophages in colorectal cancer. By eradicating these intracellular bacteria, the approach remodels the tumor immune environment and amplifies the efficacy of CD47 blockade immunotherapy.

• Optimizing Fluorescent Assays with mCherry mRNA Reporters

  2026-04-29

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) propels fluorescent protein expression with superior stability and immune evasion, making it ideal for high-fidelity cell imaging and reporter gene workflows. Learn how its advanced modifications and Cap 1 structure deliver reproducible, high-intensity signals and troubleshoot common pitfalls in mRNA-based transfection.

• Cdc42 Inhibition Attenuates Kidney Fibrosis via β-Catenin Pa

  2026-04-28

  This study identifies Cdc42 as a direct target of the natural small molecule daphnepedunin A and elucidates its role in suppressing kidney fibrosis by modulating the GSK-3β/β-catenin signaling axis. These findings provide mechanistic insight and highlight the therapeutic potential of selective Cdc42 inhibition in chronic kidney disease models.

• Antimycin A4: Dual ATP-Citrate Lyase & Mitochondrial Inhibit

  2026-04-28

  This study characterizes antimycins, including Antimycin A4, as competitive ATP-citrate lyase inhibitors derived from Streptomyces sp. It establishes their dual capacity to block both fatty acid and cholesterol biosynthesis and mitochondrial electron transport, providing a mechanistic foundation for their use in metabolism and bioenergetics research.

• Diphenyleneiodonium Chloride (SKU B6326): Reliable Redox Pro

  2026-04-27

  Diphenyleneiodonium chloride (SKU B6326) offers biomedical researchers a reproducible, high-sensitivity approach for dissecting redox enzyme activity and cAMP signaling, particularly in cell viability and oxidative stress assays. This scenario-driven article details how DPI addresses real-world workflow challenges, emphasizing its mechanistic specificity and data-backed performance benefits for advanced laboratory applications.

• MK 0893 (A3608): Reliable GCGR Antagonist for Diabetes Resea

  2026-04-27

  This article provides scenario-driven insights into the application of MK 0893 (SKU A3608), a potent glucagon receptor antagonist, for cell viability, proliferation, and cytotoxicity workflows in type 2 diabetes research. By addressing common experimental challenges and referencing peer-reviewed data, the article guides scientists toward reproducible, high-quality results using MK 0893 from APExBIO.

• Anlotinib for IADSRCT: Case Evidence and Translational Insig

  2026-04-26

  This article reviews the first documented use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in the treatment of intra-abdominal desmoplastic small round cell tumor (IADSRCT). The case report highlights significant tumor regression and manageable toxicity, providing new translational perspectives for targeting angiogenesis in rare, aggressive sarcomas.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Protocol and QC Gui

  2026-04-25

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive fluorescent detection of goat IgG in immunocytochemistry, immunohistochemistry, flow cytometry, and ELISA. It is optimized for workflows requiring high specificity and signal amplification but should not be used outside these immunodetection applications or with non-goat primary antibodies.

• TPCA-1: Advancing Selective NF-κB Pathway Inhibition in Tran

  2026-04-24

  This thought-leadership article explores the mechanistic and strategic value of the IKK-2 inhibitor TPCA-1 in inflammation and cell death research. We synthesize cutting-edge insights on NF-κB pathway modulation, highlight experimental and translational best practices, and position TPCA-1, available from APExBIO, as a pivotal tool for next-generation research in rheumatoid arthritis and cytokine regulation. Integrating the latest findings in RIPK1-regulated cell death, we offer actionable guidance for translational scientists seeking both mechanistic depth and workflow reliability.

• YTHDF1 Phase Separation Governs SSC Fate via IkB-NF-kB-CCND1

  2026-04-24

  Fang et al. (2023) reveal that liquid-liquid phase separation (LLPS) of the m6A reader protein YTHDF1 is pivotal for directing spermatogonial stem cells (SSCs) towards neural stem cell-like states by modulating translation of IkBa/b mRNAs and activating the IkB-NF-kB-CCND1 signaling axis. This study advances understanding of how protein-RNA condensates control cell fate transitions, with implications for translational neuroscience and regenerative medicine.

• RWJ 67657: Mechanistic Insights and Assay Precision in p38 M

  2026-04-23

  Explore how RWJ 67657, a selective p38 MAP kinase inhibitor, redefines assay precision and mechanistic targeting in inflammatory disease research. This article delivers a deeper analysis of kinase dephosphorylation mechanisms and practical guidance for translational workflows.

• Resveratrol Suppresses Tumor-Stroma Growth via VCAN Downregu

  2026-04-23

  This study demonstrates that resveratrol effectively inhibits the proliferative interaction between breast cancer organoids and cancer-associated fibroblasts by downregulating VCAN expression. The findings provide mechanistic insight into tumor-stroma crosstalk and highlight advanced cell proliferation assays for evaluating anti-tumor compounds in physiologically relevant 3D models.

• Efficient iPSC Differentiation to Retinal Ganglion Cells via

  2026-04-22

  This study establishes a reproducible chemically defined protocol for differentiating human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) through concurrent inhibition of SMAD and Wnt pathways. The method achieves over 80% RGC purity and minimizes inter-line variability, offering a robust platform for glaucoma and neurodegenerative disease modeling.

16240 records 1/1083 page Next 12345 下5页 Last page